KYNB today
$3.63-$0.05 (-1.43%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourLeaning Bearish
15 minLeaning Bearish
5 minStrong Bearish
Daily trend turns up above $12.20
Key levels
Resistance$4.85
Resistance$4.32
Latest news & SEC filings
AnalystMaxim Group starts Kyntra Bio coverage with Buy rating, $35 price target
All KYNB news →About Kyntra Bio
Kyntra Bio develops treatments for cancer and blood disorders. Its main candidates are FG-3246, an antibody-drug conjugate aimed at CD46 for advanced prostate cancer, along with a companion PET scan tracer called FG-3180. The company also develops roxadustat, an oral drug for anemia tied to kidney disease and certain bone marrow conditions. Roxadustat is sold in Europe, Asia, and elsewhere through partners including Astellas and AstraZeneca, while Kyntra keeps rights across North America and other unlicensed regions.
Based on the company's 10-K filed Mar 16, 2026.
Nasdaq · Healthcare
KYNTRA BIO, INC. (KYNB)
What Is the Price Target for KYNB?
SEPT Low Target
$30.00
SEPT Mid Target
$38.00
SEPT High Target
$43.00
Analyst Consensus
$38.00
Is KYNB a Buy or Sell Right Now?
Thesis
- •Revenue growing -78.3% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for KYNB.
Start Free Trial →Is KYNB Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
PEG, Analyst Consensus
Fair Value
$28.09
15
Moat Score
NONE
4/9
Piotroski Score
-20.4
Altman Z-Score
What Is Smart Money Doing with KYNB?
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| DeLucia David | officer | Sale | 52 | $348.92 | Jun 6, 2026 |
| Wettig Thane | director officer | Sale | 198 | $1K | Jun 6, 2026 |
| Wettig Thane | director officer | Sale | 2,800 | $20K | May 14, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →KYNB Growth Story
Revenue YoY
-78.3%
3yr Revenue CAGR
-64.2%
EPS Growth YoY
481.58%
FCF Growth YoY
96.5%
Revenue Trend
DECLINING
Dark Pool Trades for KYNB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for KYNB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:36:02 | $3.67 | 1,300 | $$5K | SELL |
| 18:34:28 | $3.71 | 1,060 | $$4K | MIDPOINT |
| 16:24:49 | $3.69 | 1,000 | $$4K | BUY |
| 20:12:46 | $3.88 | 5,252 | $$20K | BUY |
| 19:25:51 | $3.79 | 3,002 | $$11K | BUY |
5 dark pool trades shown · $$44K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for KYNTRA BIO, INC. (KYNB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →KYNB — frequently asked questions
What is KYNB stock price today?
KYNTRA BIO, INC. (KYNB) is at $3.63, down 1.43% (-$0.05) at the Nov 12, 2026 close.
Why is KYNB stock moving today?
Latest KYNB news — Oct 13, 2026: Maxim Group starts Kyntra Bio coverage with Buy rating, $35 price target
What is the KYNB price target?
The average analyst price target for KYNB is $38.00, ranging from $30 to $43, based on 4 analysts. Latest: Maxim Group initiates on Oct 13, 2026.
What do analysts rate KYNB?
Analyst ratings for KYNB: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did KYNB beat earnings?
KYNB last reported on Aug 13, 2026: EPS $2.96 vs -$3.18 expected — a beat of 193.1%.
What is KYNB's P/E ratio?
KYNB trades at a P/E of 0.1 vs a Healthcare average of 17.7.
Does KYNB pay a dividend?
Yes. KYNB's dividend yield is 11.12%.
What are KYNB support and resistance levels?
Resistance: $4.32, $4.85, $5.50.
What are insiders doing with KYNB?
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
What is the latest news on KYNB?
Oct 13, 2026: Maxim Group starts Kyntra Bio coverage with Buy rating, $35 price target